Structure-based peptides for detection of transthyretin amyloid fibrils and aggregates in preeclampsia
AssigneeBoard of Regents, The University of Texas System
InventorsLorena Saelices Gomez, Rose Pedretti
Life of this patent
Estimating the term…
Abstract
Provided are methods of evaluating risk for, diagnosing, and/or treating preeclampsia in a subject based on levels of transthyretin fibrils, oligomers or aggregates that can be detected using structure-specific polypeptide probes selective for aggregated transthyretin. Also provided are methods of monitoring the efficacy of a therapeutic administered to treat preeclampsia using these polypeptide probes.
Claims29
A method of determining whether a subject is at risk of preeclampsia, the method comprising:
- (a) detecting a transthyretin oligomer, fibril or molecule in a sample obtained from the subject, and (b) identifying the subject as at risk for preeclampsia if the transthyretin oligomer, fibril or molecule is detected in the sample.
A method of diagnosing a subject with preeclampsia, the method comprising:
- (a) detecting a transthyretin oligomer, fibril or molecule in a sample obtained from the subject and (b) diagnosing the subject with preeclampsia if the transthyretin oligomer, fibril or molecule is detected in the sample.
A method of monitoring an effectiveness of a therapeutic administered to a subject to treat a preeclampsia, the method comprising (a) detecting an oligomer, aggregate or fibril of transthyretin in a first sample obtained from the subject, (b) administering the therapeutic to the subject, and (c) detecting an oligomer, aggregate or fibril of transthyretin in a second sample obtained from the sample after the therapeutic is administered, wherein the therapeutic is determined to be effective if fewer oligomers, aggregates and/or fibrils of transthyretin are detected in the second sample compared to the first sample.
Dependencies are inferred from the claim text.